EPCAM and neoplasm: Provided that an αCD3 BiMAb shows no tumor-independent activation of T cells and an αCD28 BiMAb acts in a strictly co-stimulatory manner, a pan-epithelial cell surface antigen should be usable for split co-stimulation against carcinoma cells.